DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. About Tricor (Fenofibrate) without Rx (NYSE MKT: NAVB) and its subsidiary,
Macrophage Therapeutics, Inc., will hold a post-International Workshop
on Kaposi s Sarcoma Herpesvirus (KSHV) and Related Agents conference
webcast to provide investors with a more detailed look at the recently
presented Manocept™ platform clinical and pre-clinical data and results
disclosed in today’s press releases. Buy Colcrys (Colchicine) The webcast will take place on July
7, 2015 at 1:00 pm EDT. Orlistat (Orlistat) without prescription Rick Gonzalez, Navidea’s CEO and Michael
Goldberg, M.D., Macrophage Therapeutics’ CEO will host the call along
with Michael S. Captopril McGrath, M.D., Ph.D., Professor, Departments of
Laboratory Medicine, Pathology, and Medicine at the University of
California, San Francisco who will discuss the data presented.
The webcast can be accessed at the following URL: public.viavid.com/index.php?id=115204. About Herbolax () without Rx
An archived version of the webcast will be available two hours following
the presentation and can be accessed within the Investors section of
the Navidea website at .navidea.com.
About Navidea
Navidea Biopharmaceuticals, Inc. Buy Hair Loss Shampoo online (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics, therapeutics and radiopharmaceutical agents. http://asthmareview.wordpress.com Navidea is
developing multiple precision-targeted products and platforms including
Manocept™ and NAV4694 to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection,
Navidea’s first commercial product from the Manocept platform, was
approved by the FDA in March 2013 and in Europe in November 2014.
Navidea’s strategy is to deliver superior growth and shareholder return
by bringing to market novel radiopharmaceutical agents and therapeutics,
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit .navidea.com.
About Macrophage Therapeutics
Macrophage Therapeutics, Inc., a newly created subsidiary of Navidea
Biopharmaceuticals, Inc. (NAVB), is developing therapeutics using the
patented Manocept immunotherapy platform licensed from Navidea to target
over-active macrophages implicated in cancer, cardiovascular, central
nervous system, autoimmune, antiviral, and skin diseases. Manocept
specifically targets CD206, or the mannose receptor prevalent on
over-active macrophages. The technology enables highly specific targeted
delivery of active (either existing or yet to be developed) agents that
can modulate the activity of over-active macrophages that have been
implicated in many diseases. Targeted delivery should significantly
enhance a given compound’s efficacy and safety.
No comments:
Post a Comment